FOLLOW-UP OF BREAST CANCER, POSTOPERATIVE TREATMENT AND PET/CT SCAN ANALYSIS

Authors

  • Tatjana Nikoloska University Institute of Positron Emission Tomography, Skopje, North Macedonia
  • Biljana Eftimova Faculty of Medical Sciences, Goce Delcev University, Stip, North Macedonia

Keywords:

Breast Cancer, Postoperative Treatment, PET/CT Imaging, Cancer Follow-Up, Treatment Monitoring

Abstract

Breast cancer is one of the most common malignant diseases among women, both globally and in our country, and represents a major public health challenge.
It develops as a result of uncontrolled proliferation of cells in breast tissue, most often originating from the epithelium of the milk ducts or lobules. Breast cancer can remain localized or metastasize to distant organs, such as bones, lungs, liver, and brain.
In recent years, the incidence of breast cancer has increased, significant progress has been made in diagnostics and therapeutic approaches.The implementation of screening programs, modern diagnostic methods and advanced therapies has contributed to a substantial improvement in patient survival andquality of life.
Alongside comprehensive treatment and prevention strategies, early detection remain a key factor in improving outcomes
Raising awareness among the female population about regular self-examinations, mammography screening, and timely medical consultation in case of any breast changes i is essential.
Common symptoms of breast cancer include a lump in the breast or under the armpit, typically painless, hard irregularin shape andto the surrounding tissue. Other signs may include skin changes such as redness, peeling, thickening or an "orange peel" appearance, as well as alterations inbreast changes in shape or size, asymmetry, swelling or retraction. Nipple changes may occur, including.
redness, pain and itching, ordischarge, especially if blood or clear. Pain appears in the later stages, but may occasionally present early. Enlarged , hard and tender lymph nodes in the armpits, can indicate the spread of the disease.
The success of breast cancer treatment largely depends on factors such as woman's age, overallhealth,tumor type, size and location, as well as whether the cancer has metastasized. .
Early detection achieved throughtimely diagnosis and appropriate treatment initiation, is critical to favorable outcomes. Notably, three-quartersof breast cancer cases are discovered by the women themselves or their partners, 50-60% of these women delay seeking medical attention for three or more months which can negatively impact prognosis.

Author Biography

Tatjana Nikoloska, University Institute of Positron Emission Tomography, Skopje, North Macedonia

Faculty of Medical Scinces, Goce Delcev University, Stip, North Macedonia

References

Cerdas MG, Farhat J, Elshafie SI, Mariyam F, James L, Qureshi AK, Potru M, Paliwei P, Joshi MR, Abraham G, & Siddiqui HF. (2025). Exploring the Evolution of Breast Cancer Imaging: A Review of Conventional and Emerging Modalities. Cureus. 2025 Apr 22;17(4):e82762. doi: 10.7759/cureus.82762.

Ferlay, J., Colombet, M., Soerjomataram, I., et al. (2021). Cancer statistics for the year 2020: An overview. International Journal of Cancer. Advance online publication. https://doi.org/10.1002/ijc.33588

Groheux, D. (2017). FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 44, 1417–1419. https://doi.org/10.1007/s00259-017-3731-3

Hadebe B, Harry L, Ebrahim T, Pillay V, & Vorster M. (2023). The Role of PET/CT in Breast Cancer. Diagnostics (Basel). 2023 Feb 6;13(4):597. doi: 10.3390/diagnostics13040597

Hyland, C. J., Varghese, F., Yau, C., Beckwith, H., Khoury, K., Varnado, W., Hirst, G. L., Flavell, R. R., Chien, A. J., Yee, D., et al. (2020). Use of 18F-FDG PET/CT as an initial staging procedure for stage II–III breast cancer: A multicenter value analysis. Journal of the National Comprehensive Cancer Network, 18, 1510–1517. https://doi.org/10.6004/jnccn.2020.7598

Jenkins, S., Kachur, M. E., Rechache, K., et al. (2021). Rare breast cancer subtypes. Current Oncology Reports, 23, 54. https://doi.org/10.1007/s11912-021-01048-4

Kennecke, H., Yerushalmi, R., Woods, R., et al. (2010). Metastatic behavior of breast cancer subtypes. Journal of Clinical Oncology, 28, 3271–3277. https://doi.org/10.1200/JCO.2009.25.9820

Ko, H., Baghdadi, Y., Love, C., & Sparano, J. A. (2020). Clinical utility of 18F-FDG-PET/CT in staging localized breast cancer prior to initiating preoperative systemic therapy. Journal of Clinical Oncology, 38, 563. https://doi.org/10.1200/JCO.2020.38.15_suppl.563

Lee H, Choi JY, Park YH, Lee JE, Kim SW, Nam SJ, & Cho YS. (2023). Diagnostic Value of FDG PET/CT in Surveillance after Curative Resection of Breast Cancer. Cancers (Basel). 2023 May 7;15(9):2646. doi: 10.3390/cancers15092646

Macdonald, S., Oncology, R., & General, M. (2016). Breast cancer. Journal of the Royal Society of Medicine, 70, 515–517.

Roman, B. R., Randolph, G. W., & Kamani, D. (2019). Conventional thyroidectomy in the treatment of primary thyroid cancer. Endocrinology and Metabolism Clinics of North America, 48, 125–141. https://doi.org/10.1016/j.ecl.2018.11.003

Tan, W., Tao, L., Zhou, Z., et al. (2019). Tumor-to-tumor metastasis: A rare case of breast carcinoma metastasizing to a pheochromocytoma, and a literature review. Diagnostic Pathology, 14, 46. https://doi.org/10.1186/s13000-019-0816-2

Yang, X., Yang, D., Qi, X., Luo, X., & Zhang, G. (2025). Endocrine treatment mechanisms in triple-positive breast cancer: From targeted therapies to advances in precision medicine. Frontiers in Oncology, 14, 1467033. https://doi.org/10.3389/fonc.2024.1467033

Downloads

Published

2025-08-20

How to Cite

Nikoloska, T., & Eftimova, B. (2025). FOLLOW-UP OF BREAST CANCER, POSTOPERATIVE TREATMENT AND PET/CT SCAN ANALYSIS. KNOWLEDGE - International Journal , 71(4), 499–503. Retrieved from https://ojs.ikm.mk/index.php/kij/article/view/7705

Most read articles by the same author(s)

<< < 1 2